Protalix BioTherapeutics (PLX)
(Delayed Data from AMEX)
$1.15 USD
+0.06 (5.50%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $1.15 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Protalix BioTherapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 45 | 22 | 39 | 39 | 18 |
Receivables | 5 | 5 | 3 | 2 | 5 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 19 | 17 | 18 | 13 | 8 |
Other Current Assets | 1 | 1 | 1 | 2 | 2 |
Total Current Assets | 70 | 45 | 62 | 56 | 32 |
Net Property & Equipment | 5 | 5 | 5 | 5 | 5 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 3 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 2 | 2 | 2 |
Total Assets | 84 | 56 | 74 | 68 | 45 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 20 | 0 | 0 | 59 | 4 |
Accounts Payable | 24 | 18 | 23 | 21 | 18 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 13 | 9 | 5 | 16 |
Total Current Liabilities | 46 | 32 | 33 | 86 | 40 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 28 | 28 | 0 | 51 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 2 | 14 | 4 | 20 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 51 | 66 | 80 | 95 | 116 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 415 | 379 | 369 | 320 | 270 |
Retained Earnings | -382 | -390 | -375 | -347 | -341 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 34 | -11 | -6 | -27 | -70 |
Total Liabilities & Shareholder's Equity | 84 | 56 | 74 | 68 | 45 |
Total Common Equity | 34 | -11 | -6 | -27 | -70 |
Shares Outstanding | 71.50 | 49.70 | 45.50 | 33.30 | 14.80 |
Book Value Per Share | 0.47 | -0.21 | -0.13 | -0.81 | -4.75 |
Fiscal Year End for Protalix BioTherapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 45 | 48 | 45 | 41 | 48 |
Receivables | 10 | 4 | 5 | 9 | 4 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 21 | 22 | 19 | 22 | 20 |
Other Current Assets | 1 | 1 | 1 | 1 | 2 |
Total Current Assets | 77 | 75 | 70 | 73 | 74 |
Net Property & Equipment | 5 | 5 | 5 | 5 | 5 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 3 | 3 | 3 | 3 | 3 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 1 |
Total Assets | 92 | 90 | 84 | 88 | 88 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 20 | 20 | 20 | 20 | 0 |
Accounts Payable | 23 | 22 | 24 | 22 | 22 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 13 | 11 | 0 | 0 | 0 |
Total Current Liabilities | 58 | 55 | 46 | 43 | 23 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 20 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 1 | 1 | 2 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 63 | 60 | 51 | 49 | 49 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 417 | 416 | 415 | 414 | 413 |
Retained Earnings | -388 | -386 | -382 | -376 | -374 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 29 | 30 | 34 | 38 | 39 |
Total Liabilities & Shareholder's Equity | 92 | 90 | 84 | 88 | 88 |
Total Common Equity | 29 | 30 | 34 | 38 | 39 |
Shares Outstanding | 73.30 | 73.30 | 71.50 | 71.50 | 65.40 |
Book Value Per Share | 0.39 | 0.41 | 0.47 | 0.53 | 0.60 |